Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of JNJ-70033093 (Milvexian) and Digoxin in Healthy Subjects
NCT04206488Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of milvexian in thrombosis, sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) Geometric Mean Ratio of Treatment C (JNJ-70033093 + Digoxin) Relative to Treatment A (JNJ-70033093), Cmax Geometric Mean Ratio of Treatment C (JNJ-70033093 + Digoxin) Relative to Treatment B (Digoxin) and 2 more. Started Jan 2020; status: completed.
02
Drugs
milvexian
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT04206488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04206488.